Alison Shottek

Company: Modalis Therapeutics Corp.

Job title: Senior Manager - Project & Preclinical Programs

Seminars:

Panel Discussion: Discovering the Risk: Benefit Ratio of AAV Gene Therapies & Life Limiting Indications 11:30 am

• Understanding the difference in adverse event tolerance between the different target populations • Highlighting the balance between the risk associated with AAV gene therapy and the severity and life threatening capacity of the patient's disease • Curating individual risk: benefit ratios for individual patients to understand the need for the AAV gene therapy treatmentRead more

day: Day One